Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Qingjie Fu

Showing results (31-40 of 40) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 40 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2023
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, JapanTakashi Sasaki, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2024
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCCNaohiro Yasuura, Goki Suda, Masatsugu Ohara, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
Pageof 4

Showing results (31-40 of 40) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 40 results.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|June 19, 2023
Recent prevalence and characteristics of patients with hepatitis delta virus in Hokkaido, JapanTakashi Sasaki, Goki Suda, Masatsugu Ohara, et al.
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 25, 2024
Association of proteinuria with improved prognosis in unresectable hepatocellular carcinoma treated with atezolizumab and bevacizumab, and the predictive role of serum vascular endothelial growth factor D levels: A multicenter retrospective studyZijian Yang, Goki Suda, Takuya Sho, et al.
Scientific Reports|October 7, 2022
Serum IL-1β predicts de novo hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C, not during anti-cancer/immunosuppressive therapyNaoki Kawagishi, Goki Suda, Ryotaro Sakamori, et al.
Alimentary Pharmacology & Therapeutics|September 4, 2024
Positivity of high-sensitivity HBsAg test, not previous HBV infection, indicates poor prognosis in patients with non-HBV-related HCCNaohiro Yasuura, Goki Suda, Masatsugu Ohara, et al.
Scientific Reports|November 29, 2025
Simplified monitoring of sofosbuvir/velpatasvir in Japanese patients with chronic hepatitis C based on a retrospective analysis of a prospective multicenter cohortGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
The Journal of Infection|February 28, 2026
Tenofovir alafenamide prevents HBV reactivation in anticancer/immunosuppression: 24-month multicentre prospective studyGoki Suda, Masatsugu Ohara, Masaru Baba, et al.
Cancers|August 26, 2022
Efficacy and Effect on Liver Functional Reserve of Atezolizumab and Bevacizumab for Unresectable Hepatocellular Carcinoma in Patients Who Do Not Meet Eligibility Criteria of IMbrave150Takuya Sho, Goki Suda, Yoshiya Yamamoto, et al.
Journal of Medical Virology|January 4, 2023
Prophylactic tenofovir alafenamide for hepatitis B virus reactivation and reactivation-related hepatitisGoki Suda, Masaru Baba, Yoshiya Yamamoto, et al.
JHEP Reports : Innovation in Hepatology|April 17, 2025
Serum FGF21 as a predictor of response to atezolizumab and bevacizumab in HCCRisako Kohya, Goki Suda, Masatsugu Ohara, et al.
Hepatology International|August 28, 2025
Three-year overall survival in unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumabMasatsugu Ohara, Goki Suda, Risako Kohya, et al.
Pageof 4